Current Issue

Namaste
David B. Nash, MD, MBA
July 2018 Vol 11, No 5 - Editorial
Read More
Assessing the Level of Patient-Specific Treatment Recommendations in Clinical Practice Guidelines for Hemodialysis Vascular Access in the United States
Gilbert L. Queeley, PhD, Ellen S. Campbell, PhD, Askal A. Ali, PhD
July 2018 Vol 11, No 5 - Clinical, Original Research
Stakeholder Perspective
The Challenge of Maintaining Vascular Access in Patients with End-Stage Renal Disease
by Raymond L. Singer, MD, MMM, CPE
Read More
The Prevalence and Payer Costs of Potentially Avoidable Emergent Care Visits for Suspected Amniotic Membrane Rupture in Pregnant Women
Christine Ferro, CHFP, Bruce S. Pyenson, FSA, MAAA, Jocelyn Lau, MPH, Mona Kelkar, MBA, Nancy Phillips, MD, Chi-Wei Lu, PhD, Percy Yeung, PhD, Gloria Bachmann, MD
July 2018 Vol 11, No 5 - Business, Original Research
Stakeholder Perspective
Interventions to Reduce Avoidable Pregnancy-Related Emergency Department Visits
by Eliza Ng, MD
Read More
Budget Impact of Adding Vedolizumab to a Health Plan Formulary as Another First-Line Biologic Option for Ulcerative Colitis and Crohn’s Disease
Michele Wilson, MSPH, Aaron Lucas, PhD, MPH;, Ann Cameron, MA, PhD;, Michelle Luo, PhD
July 2018 Vol 11, No 5 - Business, Original Research
Read More

Hot Topics

A “Gold Standard” for Population Health? Revisiting the FDA’s Relationship with the Hippocratic Oath
Gillian Woollett, MA, DPhil , Bruce S. Pyenson, FSA, MAAA
Web Exclusives - Hot Topics

Conference Correspondent

Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
Conference Correspondent - ACR 2017, Conference Correspondent
Longer Duration of Response in MOBILITY Study with Sarilumab plus MTX in Patients with Active, Moderate-to-Severe RA
Conference Correspondent - ACR 2017, Conference Correspondent
Improvements in Remission and Low Disease Activity Achieved with Ongoing Sarilumab Treatment in Patients with RA
Conference Correspondent - ACR 2017, Conference Correspondent
Efficacy and Safety of Switching from Adalimumab to Sarilumab in Open-Label Extension of MONARCH Trial in Patients with Active RA
Conference Correspondent - ACR 2017, Conference Correspondent

Most Popular Articles

A “Gold Standard” for Population Health? Revisiting the FDA’s Relationship with the Hippocratic Oath
Gillian Woollett, MA, DPhil , Bruce S. Pyenson, FSA, MAAA
Web Exclusives - Hot Topics
Long-Term Outcomes of a Cardiovascular and Diabetes Risk-Reduction Program Initiated by a Self-Insured Employer
Nicole D. White, PharmD, CDE, Thomas L. Lenz, PharmD, FACLM, Maryann Z. Skrabal, PharmD, CDE, Jessica J. Skradski, PharmD, Louis Lipari
June 2018 Vol 11, No 4 - Clinical, Original Research
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy
Machaon M.K. Bonafede, PhD, MPH, Donna McMorrow, BS, Clare Proudfoot, PhD, Shraddha Shinde, MS, MBA, Andreas Kuznik, PhD, Chieh-I Chen, MPH
June 2018 Vol 11, No 4 - Business, Original Research
Prior Authorization for Elective Diagnostic Catheterization: The Value of Reviewers in Cases with Clinical Ambiguity
Adam C. Powell, PhD, Stephen E. Price, DPT, MBA, Khoa Nguyen, MS, Gary L. Smith, MS, James W. Long, BSBA, Uday U. Deshmukh, MD, MPH
June 2018 Vol 11, No 4 - Clinical, Original Research
Oncology Drugs Approved by the FDA in Early 2018
June 2018 Vol 11, No 4 - FDA Approvals, News & Updates

Web Exclusives

Neratinib First Extended Adjuvant Treatment for Patients with Early-Stage, HER2-Positive Breast Cancer
HER2-positive breast cancers are aggressive tumors and can spread to other parts of the body, making adjuvant therapy an important part of the treatment plan.
Read More

Select Drug Updates

Yondelis (Trabectedin) Approved for the Treatment of Unresectable or Metastatic Soft-Tissue Sarcomas
Vyvanse (Lisdexamfetamine Dimesylate): First FDA-Approved Drug for the Treatment of Adults with Binge-Eating Disorder
Varubi (Rolapitant) Approved for the Prevention of Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
Tagrisso (Osimertinib) Approved for Patients with Non–Small-Cell Lung Cancer and the EGFR T790M Mutation
View All Updates

Reader Poll

*Should the government fund healthcare cost-sharing payments to insurers to reduce the economic burden on consumers?


  • Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME